This JHU startup is working on a treatment to prevent Alzheimer’s
Technical.ly Baltimore
AgeneBio received a $7 million grant from the National Institutes of Health to begin a new round of drug trials.
Find articles and press on AgeneBio and research updates regarding hippocampal overactivity and aMCI.
$7.5 Million Grant Awarded To Start Clinical Trial For Alzheimer’s
Science Times
Johns Hopkins University (JHU) was awarded an estimated $7.5 million grant from the National Institutes of Health (NIH) to clinically test an Alzheimer’s drug, which could possibly delay or stop the onset of the disease.
JHU team gets $7.5 million to test Alzheimer’s drug
The Daily Record
A grant from the National Institutes of Health will allow researchers from the Johns Hopkins University to test a drug they hope will slow or prevent the onset of Alzheimer’s.
First drug to prevent Alzheimer’s gets clinical trial
Consumer Affairs
For the first time, a drug designed to prevent or delay the onset of Alzheimer’s disease will be tested in a major clinical trial, the first step in bringing the drug to market.
NIH Awards $7.5 Million Grant For AgeneBio HOPE4MCI Phase 3 Clinical Trial To Delay The Onset Of Alzheimer’s Dementia
BioSpace
AgeneBio, a biopharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, announced today that its HOPE4MCI Phase 3 clinical trial has received support from the National Institutes of Health (NIH).
AgeneBio’s HOPE4MCI Phase 3 trial receives support from NIH
News Medical Net
AgeneBio, a biopharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, announced today that its HOPE4MCI Phase 3 clinical trial has received support from the National Institutes of Health (NIH).
Baltimore biopharm gets NIH grant
The Daily Record
AgeneBio, a Baltimore-based biopharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, announced today that its HOPE4MCI Phase 3 clinical trial has received support from the National Institutes of Health.
Hopkins, AgeneBio to launch trial of Alzheimer’s drug in partnership with NIH
Fulton Post News
“What this could mean for thousands of patients is they may never cross over into full-blown Alzheimer’s dementia,” said Jerry McLaughlin, CEO of AgeneBio, the Baltimore company founded by a Hopkins researcher who discovered that the drug might…
NlH awards Johns Hopkins grant to clinically test drug for early Alzheimer’s
Johns Hopkins University Hub
Johns Hopkins University researchers have received an estimated $7.5 million NIH grant to test treatment to prevent or delay dementia.
Hopkins, AgeneBio to launch trial of Alzheimer’s drug in partnership with NIH
Baltimore Sun
What could be one of the first treatments to delay or prevent Alzheimer’s disease received a big boost from the National Institute on Aging, which is putting up $7.5 million to help fund the next round of trials for the…
